Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4
Status:
Completed
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of a daily, fixed-dose, 8-week course combination of
Elbasvir/Grazoprevir in treatment-naïve, non-cirrhotic patients who are mono-infected with
hepatitis C, genotype 4.